Status:

COMPLETED

Valvosoft First-In-Human Study in Severe Symptomatic Aortic Stenosis

Lead Sponsor:

Cardiawave SA

Conditions:

Aortic Valve Stenosis

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

This is a prospective, controlled, single-arm clinical investigation for the treatment of subjects with severe symptomatic aortic valve stenosis using Valvosoft® Pulsed Cavitational Ultrasound Therapy...

Detailed Description

CARDIAWAVE has developed a new non-invasive, real-time image-guided, therapeutic approach to treat patients suffering from Calcified Aortic Stenosis. CARDIAWAVE's Valvosoft device is a new ultrasound ...

Eligibility Criteria

Inclusion

  • Subjects suffering from severe symptomatic aortic valve stenosis according to ESC 2017 definition, including subjects with a bicuspid valve.
  • Patient is not eligible for TAVR/SAVR according to local Heart Team.
  • Age ≥18 years.
  • Subjects who are willing to provide a written informed consent prior to participating in the study.
  • Subjects who can comply with the study follow up or other study requirements.
  • Patient is eligible for the Valvosoft procedure according to CRC.

Exclusion

  • Subjects with any electrical device implanted.
  • Subjects with unstable arrhythmia not controlled by medical treatment.
  • Subjects with implanted mechanical valve in any position or bio prosthetic valve in aortic position.
  • Subjects with complex congenital heart disease.
  • Chest deformity.
  • Cardiogenic shock.
  • History of heart transplant.
  • Subjects requiring other cardiac surgery procedures (bypass graft surgery, mitral valve procedure, tricuspid valve procedure) within one month after treatment.
  • Thrombus in heart.
  • Acute myocardial infarction (MI), stroke or transient ischemic attack (TIA) within one month prior to enrolment\*.
  • Subjects who are pregnant or nursing.
  • Subjects who are participating in another research study for which the primary endpoint has not been reached.

Key Trial Info

Start Date :

December 23 2019

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 23 2024

Estimated Enrollment :

10 Patients enrolled

Trial Details

Trial ID

NCT04665596

Start Date

December 23 2019

End Date

May 23 2024

Last Update

August 20 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Clinical Centre of Serbia

Belgrade, Serbia, 11000